Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 2Completed 2

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Leukemia, Promyelocytic, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × tamibarotene × Clear all
NCT04905407 2025-02-24

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Syros Pharmaceuticals

Phase 2 Terminated
66 enrolled 21 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02807558 2024-12-13

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Syros Pharmaceuticals

Phase 2 Completed
155 enrolled 24 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01337154 2013-06-28

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

CytRx

Phase 2 Terminated
140 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00520208 2013-02-13

STAR-1

CytRx

Phase 2 Completed
15 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡